FML®
Fluorometholone 0.1% · ophthalmic suspension
Steroid
Approved uses
Corticosteroid-responsive inflammation of the conjunctiva, cornea, and anterior segment
1 drop 2 to 4 times daily; may be increased to 1 drop every 4 hours during the initial 24 to 48 hours
OFF-LABELNot in the FDA label for this product
Moderate to severe dry eye disease
1 drop QID for 22 days (trial regimen)
RCT · n=41 · 22 days only
Single-center double-masked randomized vehicle-controlled trial in 41 patients: at 21 days fluorometholone 0.1% improved corneal and conjunctival staining, hyperemia, and tear break-up time more than polyvinyl alcohol vehicle (P<=0.03), and after a 2-hour controlled adverse environment exposure 23.8% of treated versus 63.1% of vehicle patients worsened by one grade or more of corneal staining (P=0.03). Treatment ran 22 days, so longer-term steroid safety was not assessed.
Maintenance immunosuppression after Descemet membrane endothelial keratoplasty
After 1 month of prednisolone acetate 1%, fluorometholone 0.1% from month 2: QID through month 3, TID month 4, BID month 5, QD months 6 to 12 (trial regimen)
RCT · n=325 eyes · 1 year
Prospective randomized multicenter trial, 325 eyes: through 1 year, 0 prednisolone versus 2 fluorometholone eyes (1.4%) had a possible or probable rejection episode (P=0.17, both resolved with increased topical steroid), while IOP elevation to 24 mmHg or more, or 10 mmHg or more over baseline, occurred in 6% of fluorometholone versus 22% of prednisolone eyes (P=0.0005). One-year endothelial cell loss was comparable (30% vs 31%, P=0.50). This is the cleanest head-to-head basis for the lower IOP-rise claim against prednisolone.
Contraindications
- Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella.
- Mycobacterial ocular infection.
- Fungal diseases of ocular structures.
- Known or suspected hypersensitivity to any ingredient of the preparation or to other corticosteroids.
0.1% suspension, 5 mL, 10 mL.
Corticosteroid. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids; they are thought to act by inducing phospholipase A2 inhibitory proteins (lipocortins), which are postulated to control biosynthesis of prostaglandins and leukotrienes by inhibiting release of their common precursor, arachidonic acid. Corticosteroids inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation, and probably delay or slow healing.
Warnings & Precautions
- Increased intraocular pressure: Prolonged use of corticosteroids may increase IOP in susceptible individuals, resulting in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. If the product is used for 10 days or longer, monitor IOP routinely, even though it may be difficult in children and uncooperative patients. Use steroids with caution in the presence of glaucoma, and check IOP frequently.
- Rise in intraocular pressure in steroid responders: In clinical studies of documented steroid-responders, fluorometholone took a longer average time to produce a rise in IOP than dexamethasone phosphate, but in a small percentage of individuals a significant rise occurred within one week. The ultimate magnitude of the rise was equivalent for both drugs.
- Secondary ocular infections: Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections.
- Corneal and scleral thinning: Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and scleral thinning, and use in the presence of thin corneal or scleral tissue may lead to perforation.
- Acute purulent infection: May be masked or its activity enhanced by corticosteroid.
- Delayed healing: The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.
- Viral ocular infection: Course may be prolonged and severity worsened, including herpes simplex; a history of herpes simplex demands great caution and frequent slit lamp microscopy.
- Fungal infections of the cornea: Particularly prone to develop with long-term local corticosteroid use; suspect fungal invasion in any persistent corneal ulceration where a corticosteroid has been used or is in use, and take fungal cultures when appropriate.
- Absorption by soft contact lenses: The preservative, benzalkonium chloride 0.004%, may be absorbed by soft contact lenses; wait at least 15 minutes after instillation before inserting soft contact lenses.
- Initial prescription and renewal: Prescribing and renewal beyond 20 mL should follow examination with magnification, such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after two days, re-evaluate the patient.
Common Side Effects
In decreasing order of frequency, adverse reactions include elevation of IOP with possible development of glaucoma and infrequent optic nerve damage, posterior subcapsular cataract formation, and delayed wound healing. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported. Secondary ocular infection (bacterial, fungal and viral) has occurred, and corticosteroid-containing preparations have been reported to cause acute anterior uveitis and perforation of the globe. Transient burning and stinging upon instillation have been reported, as have allergic reactions, foreign body sensation, eyelid erythema and edema, eye discharge, eye pain, eye pruritus, increased lacrimation, rash, taste perversion, blurry vision, and visual field defect. Systemic effects are extremely uncommon.
Pregnancy: Embryocidal and teratogenic in rabbits at low multiples of the human ocular dose, with dose-related fetal loss, cleft palate, deformed rib cage, anomalous limbs, encephalocele, craniorachischisis, and spina bifida after ocular dosing on gestation days 6 to 18; no adequate human studies; use only if benefit justifies fetal risk.
Lactation: Systemically administered corticosteroids appear in human milk and could suppress growth or interfere with endogenous corticosteroid production; whether topical ocular dosing yields detectable milk levels is unknown; decide between discontinuing nursing and discontinuing the drug.
Safety and effectiveness in infants below 2 years of age not established.